Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
International Psoriasis Council
subscribe
Search

Advancing Knowledge. Improving Care.

Banner for the SID 2026 Annual Meeting in Chicago, Illinois, featuring the SID and IPC logos alongside a black-and-white photo of Chicago skyscrapers reflected in the Cloud Gate (Bean) sculpture.

The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure

2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID) | CHICAGO, ILLINOIS, UNITED STATES

May 13, 2026
 |  08:00-11:30 CST
Location: Hilton Chicago | Room: Continental B, Lobby Level

Add event to calendar
Apple   Google   Outlook   Outlook.com   Office 365   Yahoo

Agenda

Welcome and Introduction
Johann Gudjonsson, MD, PhD, United States

Intercepting Psoriasis at the Earliest Stages: Lessons from STEP-IN and GUIDE
Knut Schäkel, MD, Germany

Preventing Psoriatic Arthritis: Can Immune Interception Change the Natural Disease Course?
Shikha Singla, MD, United States

Implications of Controlling Psoriasis Inflammation: From Molecular Profiling to Comorbidities
Alex Tsoi, MS, PhD, United States

Oral Versus Biologics – Targeted or Broader Approaches?
Christopher Bunick, MD, PhD, United States

BREAK

Why Treatment Fails: Interferons, Immune Rewiring, and Biological Escape Mechanisms
Curdin Conrad, MD, Switzerland

Clinical Escape in Psoriasis: Paradoxical Reactions and Flip-Flop Phenomena
Wilson Liao, MD, United States

Case Presentations

Closing Comments
Curdin Conrad, MD, Switzerland

Program Chair

Curdin Conrad, MD

University Hospital of Lausanne

Lausanne, Switzerland

IPC Board Member

Bio

Johann Gudjonsson, MD, PhD

University of Michigan, Department of Dermatology

Ann Arbor, Michigan, United States

IPC Board Member

Bio

Program Faculty

Christopher Bunick, MD, PhD

Yale University

New Haven, Connecticut, United States

IPC Councilor

Bio

Wilson Liao, MD

University of California San Francisco

San Francisco, California, United States

IPC Councilor

Bio

Knut Schäkel, MD

Heidelberg University Hospital

Heidelberg, Germany

Bio

Shikha Singla, MD

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Bio

Alex Tsoi, MS, PhD

University of Michigan

Ann Arbor, Michigan, United States

IPC Councilor

Bio

This symposium is supported in part by:

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026